News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
543,886 Results
Type
Article (32055)
Company Profile (87)
Press Release (511744)
Multimedia
Podcasts (83)
Webinars (9)
Section
Business (167805)
Career Advice (1786)
Deals (31799)
Drug Delivery (76)
Drug Development (58649)
Employer Resources (115)
FDA (12251)
Job Trends (11734)
News (275784)
Policy (24160)
Tag
Academia (1904)
Academic (1)
Accelerated approval (5)
Adcomms (14)
Allergies (60)
Alliances (42441)
ALS (69)
Alzheimer's disease (1017)
Antibody-drug conjugate (ADC) (110)
Approvals (12295)
Artificial intelligence (241)
Autoimmune disease (19)
Automation (13)
Bankruptcy (246)
Best Places to Work (9267)
BIOSECURE Act (9)
Biosimilars (69)
Biotechnology (69)
Bladder cancer (68)
Brain cancer (21)
Breast cancer (223)
Cancer (1834)
Cardiovascular disease (137)
Career advice (1515)
Career pathing (25)
CAR-T (123)
Cell therapy (363)
Cervical cancer (16)
Clinical research (47945)
Collaboration (749)
Company closure (1)
Compensation (267)
Complete response letters (12)
COVID-19 (1822)
CRISPR (32)
C-suite (198)
Cystic fibrosis (76)
Data (1834)
Decentralized trials (2)
Denatured (24)
Depression (37)
Diabetes (219)
Diagnostics (4942)
Digital health (15)
Diversity (3)
Diversity, equity & inclusion (35)
Drug discovery (110)
Drug pricing (74)
Drug shortages (19)
Duchenne muscular dystrophy (75)
Earnings (72704)
Editorial (38)
Employer branding (14)
Employer resources (102)
Events (85626)
Executive appointments (612)
FDA (13259)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (2)
Frontotemporal dementia (6)
Funding (586)
Gene editing (77)
Generative AI (24)
Gene therapy (258)
GLP-1 (576)
Government (2900)
Grass and pollen (4)
Guidances (72)
Healthcare (14458)
Huntington's disease (12)
IgA nephropathy (22)
Immunology and inflammation (101)
Indications (25)
Infectious disease (1922)
Inflammatory bowel disease (117)
Inflation Reduction Act (8)
Influenza (38)
Intellectual property (80)
Interviews (310)
IPO (13272)
IRA (35)
Job creations (2878)
Job search strategy (1271)
Kidney cancer (8)
Labor market (23)
Layoffs (354)
Leadership (18)
Legal (6418)
Liver cancer (56)
Lung cancer (261)
Lymphoma (120)
Machine learning (3)
Management (39)
Manufacturing (252)
MASH (59)
Medical device (10105)
Medtech (10109)
Mergers & acquisitions (19081)
Metabolic disorders (547)
Multiple sclerosis (61)
NASH (13)
Neurodegenerative disease (64)
Neuropsychiatric disorders (22)
Neuroscience (1445)
NextGen: Class of 2025 (4982)
Non-profit (3480)
Now hiring (6)
Obesity (283)
Opinion (192)
Ovarian cancer (57)
Pain (66)
Pancreatic cancer (69)
Parkinson's disease (119)
Partnered (16)
Patents (186)
Patient recruitment (85)
Peanut (30)
People (45588)
Pharmaceutical (24)
Pharmacy benefit managers (10)
Phase I (14285)
Phase II (20658)
Phase III (16713)
Pipeline (1109)
Policy (109)
Postmarket research (2143)
Preclinical (6197)
Press Release (72)
Prostate cancer (101)
Psychedelics (26)
Radiopharmaceuticals (214)
Rare diseases (298)
Real estate (4301)
Recruiting (44)
Regulatory (16424)
Reports (33)
Research institute (1791)
Resumes & cover letters (282)
Rett syndrome (5)
RNA editing (3)
RSV (31)
Schizophrenia (66)
Series A (110)
Series B (64)
Service/supplier (4)
Sickle cell disease (44)
Special edition (10)
Spinal muscular atrophy (115)
Sponsored (22)
Startups (2582)
State (1)
Stomach cancer (9)
Supply chain (47)
Tariffs (31)
The Weekly (58)
Vaccines (497)
Venture capitalists (27)
Weight loss (186)
Women's health (21)
Worklife (13)
Date
Today (88)
Last 7 days (631)
Last 30 days (2181)
Last 365 days (26421)
2025 (9280)
2024 (27933)
2023 (31203)
2022 (40700)
2021 (43655)
2020 (42332)
2019 (36298)
2018 (27468)
2017 (25619)
2016 (24893)
2015 (29515)
2014 (24337)
2013 (20798)
2012 (21510)
2011 (21640)
2010 (20742)
Location
Africa (670)
Alabama (48)
Alaska (5)
Arizona (147)
Arkansas (9)
Asia (30688)
Australia (4863)
California (4711)
Canada (1596)
China (402)
Colorado (206)
Connecticut (245)
Delaware (115)
Europe (69195)
Florida (759)
Georgia (168)
Idaho (42)
Illinois (406)
India (23)
Indiana (254)
Iowa (6)
Japan (156)
Kansas (80)
Kentucky (16)
Louisiana (8)
Maine (59)
Maryland (638)
Massachusetts (3545)
Michigan (189)
Minnesota (282)
Mississippi (1)
Missouri (57)
Montana (23)
Nebraska (19)
Nevada (51)
New Hampshire (48)
New Jersey (1764)
New Mexico (18)
New York (1345)
North Carolina (802)
North Dakota (5)
Northern California (2082)
Ohio (159)
Oklahoma (13)
Oregon (24)
Pennsylvania (1055)
Puerto Rico (9)
Rhode Island (26)
South America (957)
South Carolina (19)
Southern California (1768)
Tennessee (90)
Texas (679)
United States (18363)
Utah (159)
Virginia (112)
Washington D.C. (47)
Washington State (435)
West Virginia (3)
Wisconsin (47)
543,886 Results for "alza corporation acquired by j and j".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Approvals
J&J Steps Into Crowded Myasthenia Gravis Market With FDA Nod
With Imaavy, J&J will go toe-to-toe with fellow Big Pharma AstraZeneca, which owns Soliris and Ultomiris.
May 1, 2025
·
2 min read
·
Tristan Manalac
FDA
J&J Wins Crohn’s Expansion for Tremfya as Stelara Biosimilars Enter US Market
The label expansion could help J&J establish Tremfya as a successor to Stelara, which is now facing a growing biosimilar challenge.
March 21, 2025
·
2 min read
·
Tristan Manalac
Tariffs
J&J CEO Duato Urges Tax Fix, Not Tariffs To Drive US Pharma Manufacturing
In the company’s first-quarter earnings call Tuesday, J&J CEO Joaquin Duato said there’s a better way to encourage drug manufacturing in the U.S. than President Donald Trump’s threatened pharma tariffs.
April 15, 2025
·
3 min read
·
Annalee Armstrong
Earnings
J&J Beats Q1 Analyst Estimates Thanks To Tremfya, Carvykti, While Stelara Fades
J&J opened Q1 2025 pharma earnings Tuesday, reporting sales of $21.9 billion and diluted earnings per share of $4.54. The medicines unit provided $13.9 billion while the medtech unit generated the remaining $8 billion.
April 15, 2025
·
2 min read
·
Annalee Armstrong
Depression
J&J Axes Late-Stage Depression Trial After Underwhelming Efficacy
Analysts do not believe the Phase III stumble for aticaprant will derail J&J’s broader neuroscience strategy, particularly given its recent $14.6 billion acquisition of Intra-Cellular Therapeutics and the success of Spravato for treatment-resistant depression.
March 7, 2025
·
2 min read
·
Tristan Manalac
Complete response letters
J&J’s FDA Bid for Subcutaneous Rybrevant Falls Short
The FDA cited issues with a manufacturing facility as the reason for the rejection. J&J is currently “working closely” with the regulator to resolve these problems.
December 17, 2024
·
2 min read
·
Tristan Manalac
Regulatory
J&J Poised to Challenge Argenx With Myasthenia Gravis Filing for Nipocalimab
J&J gained rights to the FcRn blocker nipocalimab when it acquired Momenta Pharmaceuticals in August 2020 for $6.5 billion.
August 30, 2024
·
2 min read
·
Tristan Manalac
Earnings
J&J Sets Tariff Tone as Q1 Earnings Begin To Roll In
Analysts have had to throw out their assumptions for the biopharma industry’s recovery heading into the first quarter earnings period given the ongoing tariff drama.
April 16, 2025
·
3 min read
·
Annalee Armstrong
CAR-T
J&J, Legend Shrug Off Carvykti’s Challengers With New Phase III Data
With nearly 90% of patients showing no detectable cancer cells after treatment, J&J and Legend’s Carvykti could stave off competition from emerging CAR T therapies such as Gilead and Arcellx’s anito-cel.
December 11, 2024
·
2 min read
·
Tristan Manalac
CAR-T
Gilead/Arcellx’s Anito-Cel’s Differentiated Safety Profile Challenges J&J/Legend’s Carvykti
Anito-cel has shown no signs of delayed neurotoxicity at around 9 months of follow-up, hinting at a safety profile that could set it apart from J&J and Legend’s Carvykti.
December 10, 2024
·
2 min read
·
Tristan Manalac
1 of 54,389
Next
